Trans Genic Inc. (2342.T)
JPY 189.0
(2.72%)
JPY 189.0
(2.72%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 89.43 Million JPY | 455.61% |
| 2022 | -25.15 Million JPY | -101.37% |
| 2021 | 1.83 Billion JPY | 105.7% |
| 2020 | 893.19 Million JPY | 413.33% |
| 2019 | 174 Million JPY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -103 Million JPY | -377.08% |
| 2023 Q2 | -18.43 Million JPY | -117.23% |
| 2023 FY | 89.43 Million JPY | 455.61% |
| 2023 Q3 | -36.26 Million JPY | -96.73% |
| 2023 Q1 | 106.95 Million JPY | 159.93% |
| 2023 Q4 | 37.17 Million JPY | 202.52% |
| 2022 Q3 | 18.53 Million JPY | -87.78% |
| 2022 FY | -25.15 Million JPY | -101.37% |
| 2022 Q4 | -178.45 Million JPY | -1062.96% |
| 2022 Q2 | 151.68 Million JPY | 0.0% |
| 2021 FY | 1.83 Billion JPY | 105.7% |
| 2020 FY | 893.19 Million JPY | 413.33% |
| 2019 FY | 174 Million JPY | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 596.82 Million JPY | 85.015% |
| PRISM BioLab Co.,LTD | -496.86 Million JPY | 118.0% |
| GNI Group Ltd. | 13.1 Billion JPY | 99.318% |
| Linical Co., Ltd. | 725.72 Million JPY | 87.676% |
| MEDINET Co., Ltd. | -1.42 Billion JPY | 106.272% |
| Soiken Holdings Inc. | -610 Million JPY | 114.661% |
| Cytori Cell Research Institute, Inc. | -772.74 Million JPY | 111.574% |
| AnGes, Inc. | -11.96 Billion JPY | 100.747% |
| OncoTherapy Science, Inc. | -1.12 Billion JPY | 107.98% |
| Nxera Pharma Co., Ltd. | -9.52 Billion JPY | 100.939% |
| Immuno-Biological Laboratories Co., Ltd. | 104.29 Million JPY | 14.25% |
| NanoCarrier Co., Ltd. | -864.41 Million JPY | 110.346% |
| Carna Biosciences, Inc. | -1.11 Billion JPY | 108.007% |
| CanBas Co., Ltd. | -1.26 Billion JPY | 107.087% |
| D. Western Therapeutics Institute, Inc. | -798.55 Million JPY | 111.2% |
| RaQualia Pharma Inc. | -337.36 Million JPY | 126.51% |
| Chiome Bioscience Inc. | -1.2 Billion JPY | 107.421% |
| Kidswell Bio Corporation | -1.33 Billion JPY | 106.696% |
| PeptiDream Inc. | 6.77 Billion JPY | 98.68% |
| Oncolys BioPharma Inc. | -1.92 Billion JPY | 104.634% |
| Ribomic Inc. | -1.11 Billion JPY | 108.013% |
| SanBio Company Limited | -4.53 Billion JPY | 101.97% |
| Healios K.K. | -3.37 Billion JPY | 102.647% |
| BrightPath Biotherapeutics Co., Ltd. | -1.15 Billion JPY | 107.743% |
| Kubota Pharmaceutical Holdings Co., Ltd. | -1.39 Billion JPY | 106.418% |
| Delta-Fly Pharma, Inc. | -1.4 Billion JPY | 106.375% |
| StemRIM | -2.07 Billion JPY | 104.308% |
| CellSource Co., Ltd. | 1.22 Billion JPY | 92.678% |
| FunPep Company Limited | -994 Million JPY | 108.998% |
| Kringle Pharma, Inc. | -888.76 Million JPY | 110.063% |
| Stella Pharma Corporation | -760.3 Million JPY | 111.763% |
| TMS Co., Ltd. | -943.25 Million JPY | 109.482% |
| Noile-Immune Biotech Inc. | -775.39 Million JPY | 111.534% |
| Cuorips Inc. | -588.48 Million JPY | 115.198% |
| K Pharma,Inc. | 366.05 Million JPY | 75.568% |
| Takara Bio Inc. | 3 Billion JPY | 97.022% |
| ReproCELL Incorporated | -409.29 Million JPY | 121.851% |
| PhoenixBio Co., Ltd. | 11.06 Million JPY | -708.424% |
| StemCell Institute Inc. | 413.75 Million JPY | 78.385% |
| Japan Tissue Engineering Co., Ltd. | 144.5 Million JPY | 38.11% |
| CellSeed Inc. | -697.77 Million JPY | 112.817% |